Corticotropin-releasing hormone test predicts the outcome of unilateral adrenalectomy in primary bilateral macronodular adrenal hyperplasia

[11] Cavagnini F(2021)Loss of KDM1A in GIP-dependent primary bilateral macronodular adrenal hyperplasia with Cushing’s syndrome: a multicentre, retrospective, cohort study Lancet Diabetes Endocrinol 9 E1784-E1792

[12] Boscaro M(2014)ARMC5 mutations are common in familial bilateral macronodular adrenal hyperplasia J Clin Endocrinol Metab 99 2105-2114

[13] Arnaldi G(2013)ARMC5 mutations in macronodular adrenal hyperplasia with cushing’s syndrome N Engl J Med 369 959-968

[14] Lacroix A(2017)A multicenter experience on the prevalence of ARMC5 mutations in patients with primary bilateral macronodular adrenal hyperplasia: from genetic characterization to clinical phenotype Endocrine 55 E926-E935

[15] Feelders RA(2015)ARMC5 mutations in a large cohort of primary macronodular adrenal hyperplasia: clinical and functional consequences J Clin Endocrinol Metab 100 808-2993

[16] Stratakis CA(2015)An analysis of different therapeutic options in patients with Cushing’s syndrome due to bilateral macronodular adrenal hyperplasia: a single-centre experience Clin Endocrinol (Oxf) 82 2985-138

[17] Nieman LK(2022)Clinical, pathophysiologic, genetic, and therapeutic progress in primary bilateral macronodular adrenal hyperplasia Endocr Rev 104 129-695

[18] Lacroix A(2019)Long-term outcome of primary bilateral macronodular adrenocortical hyperplasia after unilateral adrenalectomy J Clin Endocrinol Metab 163 142-704

[19] Boronat M(2010)Aberrant cortisol regulations in bilateral macronodular adrenal hyperplasia: a frequent finding in a prospective study of 32 patients with overt or subclinical Cushing’s syndrome Eur J Endocrinol 8 690-94

[20] Lucas T(2013)ACTH-independent macronodular adrenocortical hyperplasia reveals prevalent aberrant in vivo and in vitro responses to hormonal stimuli and coupling of arginine-vasopressin type 1a receptor to 11β-hydroxylase Orphanet J Rare Dis 28 5593-138

[11] Cavagnini F(2021)Loss of KDM1A in GIP-dependent primary bilateral macronodular adrenal hyperplasia with Cushing’s syndrome: a multicentre, retrospective, cohort study Lancet Diabetes Endocrinol 9 E1784-E1792

[12] Boscaro M(2014)ARMC5 mutations are common in familial bilateral macronodular adrenal hyperplasia J Clin Endocrinol Metab 99 2105-2114

[13] Arnaldi G(2013)ARMC5 mutations in macronodular adrenal hyperplasia with cushing’s syndrome N Engl J Med 369 959-968

[14] Lacroix A(2017)A multicenter experience on the prevalence of ARMC5 mutations in patients with primary bilateral macronodular adrenal hyperplasia: from genetic characterization to clinical phenotype Endocrine 55 E926-E935

[15] Feelders RA(2015)ARMC5 mutations in a large cohort of primary macronodular adrenal hyperplasia: clinical and functional consequences J Clin Endocrinol Metab 100 808-2993

[16] Stratakis CA(2015)An analysis of different therapeutic options in patients with Cushing’s syndrome due to bilateral macronodular adrenal hyperplasia: a single-centre experience Clin Endocrinol (Oxf) 82 2985-138

[17] Nieman LK(2022)Clinical, pathophysiologic, genetic, and therapeutic progress in primary bilateral macronodular adrenal hyperplasia Endocr Rev 104 129-695

[18] Lacroix A(2019)Long-term outcome of primary bilateral macronodular adrenocortical hyperplasia after unilateral adrenalectomy J Clin Endocrinol Metab 163 142-704

[19] Boronat M(2010)Aberrant cortisol regulations in bilateral macronodular adrenal hyperplasia: a frequent finding in a prospective study of 32 patients with overt or subclinical Cushing’s syndrome Eur J Endocrinol 8 690-94

[20] Lucas T(2013)ACTH-independent macronodular adrenocortical hyperplasia reveals prevalent aberrant in vivo and in vitro responses to hormonal stimuli and coupling of arginine-vasopressin type 1a receptor to 11β-hydroxylase Orphanet J Rare Dis 28 5593-138